54 000 TB deaths in SA in 2024, according to WHO
Around 54 000 people died of TB in South Africa in 2024 and 249 000 fell ill with the disease, according to new estimates from the World Health Organization. Marcus Low reports.
SA and Indonesia team up on massive asymptomatic TB study
Over the last decade, there’s been growing evidence that people can have TB without having any symptoms. But there is still much uncertainty over how such asymptomatic TB functions in the body and how infectious it is. An ambitious study, set to be conducted in South Africa and Indonesia, is trying to find some answers. Elri Voigt reports.
#InTheSpotlight | TB’s tight grip: Why this curable disease is so hard to treat
TB can be cured, but ridding the body of the bug often takes many months and usually requires taking four or more different medicines. In this Spotlight special briefing, Elri Voigt zooms in on what makes the TB bacterium so hard to beat.
Tongue swabs – Where might these experimental TB tests eventually fit in?
While likely years away from widespread use, a test for TB that relies on a simple tongue swab instead of a person having to cough up sputum is showing promise. Elri Voigt takes stock of how the test works and asks experts what its future role might be.
#InTheSpotlight | SA has started a TB revolution – can we see it through?
Over the last decade, it has become clear that South Africa’s progress against TB depends on diagnosing more people more quickly. In this Spotlight special briefing, Marcus Low asks how we can best go about it.
#InTheSpotlight | Beyond the hype, what might AI actually mean for healthcare in SA?
With varying degrees of success, artificial intelligence has begun to play the role of research assistant, radiologist, health educator, and even therapist. In this Spotlight special briefing, Jesse Copelyn tries to see past the hype and pin-points the most immediate implications of these new technologies for healthcare in South Africa.
Competition law has again worked to fight a bad drug patent, but we need other solutions
A Competition Commission probe recently resulted in a patent on an important tuberculosis medicine being dropped in South Africa. Twenty years ago, a similar Competition Commission case resulted in a settlement that helped drive down the prices of several antiretrovirals, thereby helping to set the stage for the country’s HIV treatment programme. Fatima Hassan and Leena Menghaney connect the dots between the two landmark cases and map out what has and has not changed over the last two decades.
#InTheSpotlight | Diabetes is a leading killer in SA – yet we don’t know who has it or where they are
Diabetes is the second leading cause of death in South Africa after tuberculosis, according to Statistics South Africa. It is the leading cause of death in women. Yet, despite being a major driver of deaths and illness, we do not have a clear picture of how many people in the country have diabetes or how many people are receiving diabetes care. This leaves our health system ill-equipped to handle the growing diabetes crisis.
New TB drug shows promise, but experimental vaccine disappoints
While three new tuberculosis (TB) medicines have been registered in South Africa over the last decade, TB treatment still comes with several side effects and requires taking multiple different medicines, typically for six or more months. The search for better TB medicines got a boost last week with the presentation of promising findings from a study conducted in South Africa on an experimental drug called quabodepistat. Elri Voigt reports on this and other TB studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado.
EDITORIAL | With elections and NHI, this is a big year for healthcare in SA
South Africa is barrelling towards its most consequential and most competitive national and provincial elections since 1994. Spotlight editor Marcus Low asks what is on the line in these elections from a healthcare perspective and argues that the stakes are particularly high when it comes to NHI and the Gauteng and KwaZulu-Natal provincial health departments.
Antibiotic slashes risk of drug-resistant TB in kids, finds major SA study
Tuberculosis (TB) preventive therapy has been transformed in recent years, with treatment duration having been cut from six or more months to just three or one. Progress in developing new treatments to prevent drug-resistant forms of TB has however lagged behind, especially in children. Elri Voigt unpacks findings from a major new TB prevention study presented at the Union World Conference on Lung Health last week and plans for another important preventive therapy trial set to start soon.
Interview: “Someone had to do it”, says SA TB activist on Time 100 list
At the age of 19 Phumeza Tisile contracted multidrug-resistant tuberculosis. For four years she battled the disease, losing her hearing in the process. At one stage, a doctor told her to visit a priest and prepare her soul for death. Recently, Tisile (now 33) made it on to TIME magazine’s 2023 TIME100 Next list, as one of 100 emerging leaders round the world who are “shaping the future and defining the next generation of leadership”. Sue Segar chatted to Tisile about her remarkable journey.
